Formulation Development
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Bicycle Therapeutics plc (NASDAQ: BCYC) recently announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA)…
Peapod Bio & Enamine Announce Strategic Collaboration
Peapod Bio Inc. recently announced a strategic collaboration with Enamine, enabling Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s…
Medicus Pharma Completes Enrollment of 90 Patients for Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. recently announced its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat nodular basal…
FDA Approves First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults & Adolescents
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. recently announced the US FDA has approved NUZOLVENCE (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication…
Nanexa & Moderna Enter License & Option Agreement for the Development of PharmaShell®-Based Products
Nanexa AB recently announced the signing of a license and option agreement with Moderna, Inc. Under the agreement, Moderna receives a license to use Nanexa’s…
2026 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.
DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
Hibreniguss Terefe, PhD, says although the unique challenges of orphan drug development are amplified by compressed timelines and limited patient populations, common pitfalls also serve as cautionary tales for other areas of drug development.
3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
ORAL SUSPENSIONS - A New Standard in Oral Suspensions: Leveraging Novel Excipients for FDA Approval
Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).
DRUG DELIVERY - PharmaShell®: Enabling Once-Monthly Therapeutics With Atomic Precision Coatings
Anders Johansson, PhD, Polla Rouf, PhD, and Joel Hellrup, PhD, review an innovative drug delivery system that uses nanometer-thin, inorganic coatings to turn short-acting drugs into long-acting injectables.
INJECTABLE DEVICES - Delivering Tomorrow’s Injectables to Patients Today: Responding to a New Era of Demand With Purpose-Built Capabilities
Tommy Schornak examines how evolving therapeutic modalities, delivery systems, and regulatory expectations are reshaping the fill finish landscape.
PLATFORM TECHNOLOGY - Developing Innovative Solutions to One of the Top Public Health Threats: Antibacterial Resistance
Jennifer Schneider, PhD, believes immunotherapy holds the potential to revolutionize the treatment of “hard to treat,” chronic, and often recalcitrant infections.
Bora Pharmaceuticals & Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
Bora Pharmaceuticals Co., Ltd. and Corealis Pharma Inc. have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and…
Enterprise Therapeutics Publishes Results of Phase 1 Study of a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrsosis1. The paper, titled ETD001, a long-acting inhaled…
Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients From Phase 2a Trial of TAZBENTETOL
Spinogenix, Inc. recently announced encouraging results from its completed Phase 2a trial evaluating Tazbentetol (formerly named SPG302) for the treatment of Alzheimer’s disease (AD). Once-daily…
TScan Therapeutics Announces Positive Updated Data From Phase 1 Heme Trial
TScan Therapeutics, Inc. recently announced updated results from the ongoing ALLOHA Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic…
Rigel Presents Updated Data From Ongoing Phase 1b Study Evaluating R289 in Patients With Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual…
Kymera Therapeutics Announces Positive Results From Phase 1b Clinical Trial of a First-in-Class Oral STAT6 Degrader in Patients With Moderate to Severe Atopic Dermatitis
Kymera Therapeutics, Inc. recently announced positive clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader…
Kelun-Biotech & Crescent Biopharma Announce Strategic Partnership to Develop & Commercialize Novel Oncology Therapeutics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Crescent Biopharma, Inc. recently announced they have entered into a strategic partnership to develop and commercialize oncology therapeutics, including…
